Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

POVIDONE - IODINE

All products: not a benefit

Betadine · DIN 00158348 · 10% · Top Sol

Listed, not a benefitHealth Canada: not checked yet (expand to check)
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Health Canada: not checked yet (expand to check)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Betadine · DIN 00158348 Manufacturer: Purdue Pharma; listing date 1996-10-01 Health Canada: not checked yet (expand to check)
Check this DIN again

Betadine: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada: not checked yet (expand to check) · Verify on the e-Formulary ↗ (DIN 00158348)

Source record
DIN 00158348: Betadine Raw flags: notABenefit=Y, sec3=Y, selfMed=Y Item: 840416007; group id 832; item number 2025; lccId None; manufacturer id PFP Source form: Top Sol; strength: 10% Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; self-medication (OTC-type) product Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00158348
Interchangeable products
Proviodine · DIN 00172944 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00158348
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (84:04:16 Other Anti-Infectives) and how they are covered

Matched class: 84:04:16 Other Anti-Infectives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: METRONIDAZOLE & NYSTATIN, SILVER SULFADIAZINE Some products covered without a code (check the product listing): METRONIDAZOLE 84:04:16 Other Anti-Infectives

METRONIDAZOLE

· 5 products · General benefit (3), Off-Formulary Interchangeable, not an ODB benefit (2) · strengths: 1%, 0.75%, 10% · Top Cr, Top Gel, Vag Cr-App

METRONIDAZOLE & NYSTATIN

· 2 products · General benefit · strengths: 500mg & 100000U/g, 500mg & 100000U · Vag Cr-App, Vag Sup

SILVER SULFADIAZINE

· 2 products · General benefit · strengths: 1% · Cr, Cr-50g Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:04:16
Full class listing Related classes: 84:04:04 Antibiotics, 84:04:08 Fungicides, 84:04:12 Parasiticides Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
Product monograph unavailable: no marketed product found

Other review policies

For Betadine: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026